​

Black Diamond Therapeutics (BDTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Black Diamond Therapeutics Revenue Highlights

00

Black Diamond Therapeutics Revenue by Period

Black Diamond Therapeutics Revenue by Year

DateRevenueChange
2024-12-31-100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Black Diamond Therapeutics generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Black Diamond Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30-100.00%
2025-06-30--100.00%
2025-03-31$70.00M13465.89%
2024-12-31$516.00K100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$4.89M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Black Diamond Therapeutics generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Black Diamond Therapeutics Revenue Breakdown

Black Diamond Therapeutics Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceMar 25
Reportable Segment$70.00M

Black Diamond Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Reportable Segment (100.00%).

Black Diamond Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ENTAEnanta Pharmaceuticals$65.32M$18.31M
FENCFennec Pharmaceuticals$47.54M$9.65M
FHTXFoghorn Therapeutics$22.60M$8.15M
IVAInventiva$17.48M$2.73M
AVTXAvalo Therapeutics$441.00K-
IMRXImmuneering--
BDTXBlack Diamond Therapeutics--
AARDAardvark Therapeutics--
CRBUCaribou Biosciences--
TNYATenaya Therapeutics--
ABEOAbeona Therapeutics--

BDTX Revenue FAQ

What is Black Diamond Therapeutics’s yearly revenue?

Black Diamond Therapeutics's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. BDTX's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Black Diamond Therapeutics’s quarterly revenue?

Black Diamond Therapeutics's quarterly revenue for Q3 2025 was $0, a 100.00% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $0, a -100.00% decrease from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). BDTX's quarterly revenue for Q1 2025 was $70M, a 13465.89% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Black Diamond Therapeutics’s revenue growth rate?

Black Diamond Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.